Literature DB >> 4045696

Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit.

I Yamamoto, K Iwata, M Nakashima.   

Abstract

Therapeutic dose (20, 40 and 80 micrograms/man) of clenbuterol hydrochloride, a beta 2-adrenergic stimulant, was orally administered to healthy volunteers, and the unmetabolized drug in plasma and urine was determined by enzyme immunoassay. The plasma levels of clenbuterol reached the maximum value of 0.1, 0.2 and 0.35 ng/ml, respectively, in a dose-dependent manner within 2.5 h, which lasted for over 6 h after the administration. The half-life of clenbuterol in plasma was estimated to be about 35 h. When the drug was orally administered repeatedly to men twice a day, the plasma level reached the plateau within 4 d after the initial administration. At that time, the plasma levels of the unchanged form were 0.2 to 0.3 ng/ml and 0.5 to 0.6 ng/ml at doses of 20 and 40 micrograms/man, respectively. The bound ratio of the drug to plasma protein was estimated to be 89-98% at a single administration of 80 micrograms of the drug. The cumulative urinary excretion of unchanged compound corresponded to about 20% of the administered dose as measured at 72 h following a single oral administration. When clenbuterol hydrochloride was orally administered to rats at a dose of 2 micrograms/kg, the plasma level reached the maximum at about 1 h after the administration. In rabbits, the plasma concentrations reached the maximum value of about 0.2 and 0.8 ng/ml within 2 h following administration of clenbuterol hydrochloride at doses of 0.5 and 2 micrograms/kg, respectively. The half-life of clenbuterol in plasma was about 30 h in rats and about 9 h in rabbits.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045696     DOI: 10.1248/bpb1978.8.385

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  7 in total

Review 1.  Enantioselective disposition of albuterol in humans.

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

2.  Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein.

Authors:  Joseph R Patterson; Warren D Hirst; Jacob W Howe; Christopher P Russell; Allyson Cole-Strauss; Christopher J Kemp; Megan F Duffy; Jared Lamp; Andrew Umstead; Michael Kubik; Anna C Stoll; Irving E Vega; Kathy Steece-Collier; Yi Chen; Anne C Campbell; Catherine L Nezich; Kelly E Glajch; Caryl E Sortwell
Journal:  NPJ Parkinsons Dis       Date:  2022-05-24

3.  Bambuterol and terbutaline in human cerebrospinal fluid and plasma.

Authors:  B Rosberg; C Schröder; L Nyberg; J Rosenborg; J E Wirén
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Prediction of the therapeutic dose for beta-stimulants based on preclinical data: application of oral dosage forms and aerosols to asthmatic patients.

Authors:  K Ito; N Yajima; H Ohtani; Y Yamada; K Nakamura; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

Review 5.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

6.  Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol.

Authors:  Jatin G Burniston; Neil Chester; William A Clark; Lip-Bun Tan; David F Goldspink
Journal:  Muscle Nerve       Date:  2005-12       Impact factor: 3.217

7.  Unsuspected Clenbuterol Toxicity in a Patient Using Intramuscular Testosterone.

Authors:  Matthew K Griswold; Eike Blohm; Roderick Cross; Edward W Boyer; Jennifer L Carey
Journal:  Clin Pract Cases Emerg Med       Date:  2017-05-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.